11.1 Trial Registration and Results Disclosure: US, EU, and ICMJE
Key Takeaways
For an Applicable Clinical Trial subject to 42 CFR Part 11, the responsible party generally submits registration information to ClinicalTrials.gov no later than 21 calendar days after the first human participant is enrolled.
Required US summary results are generally due no later than one year after the primary completion date, with specified delayed-submission certifications, extensions, and other provisions; determine whether the study and responsible party are in scope.
Under EU Clinical Trials Regulation Article 37(4), the scientific summary is generally due within one year after the end of the trial and is accompanied by a lay summary; current EU guidance provides a six-month pediatric timeframe with a stated scientific exception for certain trials.
ICMJE publication policy is broader and earlier than the US statutory ACT rule: clinical trials should be registered in an acceptable public registry at or before first participant consent for enrollment, including phase 1 trials.
Registry posting that meets ICMJE’s described limits is not treated as prior publication, but registry, manuscript, protocol, and data-sharing records should be reconciled.
Trial Registration and Results Disclosure: US, EU, and ICMJE
Trial-transparency duties arise from different authorities. A study may be subject to US law, EU regulation, funder policy, ethics commitments, journal policy, protocol promises, or several at once. Do not apply one deadline to every trial.
United States: FDAAA 801 and 42 CFR Part 11
The Final Rule implements statutory requirements for specified Applicable Clinical Trials (ACTs). Scope depends on product type, study phase and design, jurisdictional nexus, approval status, and other definitions. Certain controlled interventional studies of FDA-regulated drugs, biologics, and devices are included; phase 1 drug trials and small device feasibility studies are generally outside the ACT definition. Other NIH or sponsor policies may still require registration.
The responsible party—the sponsor or a properly designated principal investigator—has the submission obligation. For an ACT subject to the rule:
- registration information is generally due no later than 21 calendar days after enrollment of the first human participant;
- specified record fields require periodic and event-driven updates;
- summary results are generally due no later than one year after the primary completion date;
- specified delayed-submission certifications may apply for an unapproved product or unapproved use, and extensions may be requested for good cause under the rule;
- adverse-event and other required results information must follow the structured requirements.
The primary completion date is tied to final data collection for the primary outcome measures, not the date the manuscript is accepted, the database is locked, or the final study report is signed.
Do not state that every study on ClinicalTrials.gov is an ACT or that every ACT has exactly the same deadline after all available provisions. Use the current official checklist, record, and legal or regulatory specialists. Civil monetary penalty amounts are inflation adjusted; avoid memorizing a stale dollar figure.
Results do not wait for journal acceptance
A planned manuscript does not suspend a legal results deadline. Build registry drafting, quality control, and investigator review into the publication timeline. Reconcile participant flow, baseline characteristics, outcome definitions, time points, units, adverse events, and analysis populations between the registry and manuscript. Explain legitimate differences, such as later follow-up or a different analysis cutoff.
The ICMJE does not treat qualifying registry results as prior publication when they are limited to a brief structured abstract or tables covering enrolled participants, baseline characteristics, primary and secondary outcomes, and adverse events. A team should meet transparency duties and tell the journal about public results rather than delay required posting to protect novelty.
European Union: CTR and CTIS
For trials governed by Regulation (EU) No 536/2014, Article 37(4) requires a summary of results in the EU database within one year after the end of the clinical trial, accompanied by a summary written for laypersons. Annexes IV and V describe content.
Current European Commission guidance states that pediatric trial results are generally submitted within six months after the end of the trial. It also describes an exception: for a pediatric trial outside the specified scope of Article 46(1) of the Paediatric Regulation, when submission within six months is scientifically impossible as described in the protocol, submission is due no later than 12 months after trial end.
Use the official “end of trial” definition and CTIS process for the particular trial. Do not replace it with the US primary-completion-date concept. Transitional studies, early termination, temporary halt, deferrals, older EudraCT obligations, and member-state requirements may require specialist review.
The lay summary is not a promotional article. It should accurately communicate the trial and follow the current CTIS or Commission guidance. A peer-reviewed plain-language summary does not automatically satisfy the regulatory deliverable.
ICMJE publication policy
ICMJE recommends that medical-journal editors require registration of clinical trials in an acceptable public registry at or before the time of first patient consent for enrollment as a condition of consideration for publication. Its trial definition covers prospective assignment of people or groups to a health-related intervention to study a health outcome, including phase 1 trials. It is broader and earlier than the ACT deadline.
Acceptable registries include WHO ICTRP primary registries that meet ICMJE requirements and ClinicalTrials.gov. The entry must be public and complete enough to meet the required registration dataset. A locked or nonpublic record may not satisfy publication policy.
This is editorial policy, not US registration law. ICMJE notes that rare exceptions may be considered, with delayed registration and an explanation, but failure to register prospectively risks inadmissibility. Therefore, “automatic rejection under all circumstances” is too categorical, while prospective registration remains the correct operational standard.
Registration record maintenance
Registration is not a one-time clerical task. Define ownership for:
- initial registration and quality review;
- recruitment, status, contact, completion-date, outcome, and protocol updates;
- results submission and quality-control comments;
- data-sharing-plan updates;
- links to resulting publications;
- reconciliation with protocol amendments and manuscripts;
- retention of confirmation and change history.
If the data-sharing plan changes, ICMJE expects the registry record and submitted or published statement to be updated. If an outcome changes, preserve timing and rationale rather than overwriting the history in a way that hides selective reporting.
Applied decision sequence
For a trial-transparency scenario, ask:
- Which country or region and which authority apply?
- Is the study an ACT, an EU CTR trial, an ICMJE-defined clinical trial, or another category?
- Who is the responsible party or sponsor?
- Is the trigger first enrollment, first consent, primary completion, or end of trial?
- Do a certification, extension, transition, or exception provision apply?
- What must be public, and when?
- Do the registry, protocol, statistical plan, manuscript, and data-sharing statement agree?
Important
Use the date and definition from the controlling rule. “Within 12 months” can mean different triggers in US and EU systems, and ICMJE prospective registration is earlier than the US ACT filing deadline.
For an Applicable Clinical Trial subject to 42 CFR Part 11, when is initial registration information generally due?
No later than 21 calendar days after enrollment of the first human participant
One year after the primary completion date
At manuscript acceptance
After FDA product approval
What is the general EU CTR timing for a pediatric trial results summary, subject to the exception described in current Commission guidance?
Twenty-one days after first enrollment
Within six months after the end of the clinical trial
One year after the US primary completion date in every case
Only after journal publication
How does ICMJE registration policy differ from the US ACT rule?
ICMJE applies only after FDA approval.
ICMJE permits registration at manuscript submission.
ICMJE calls for public registration at or before first participant consent for enrollment across its broader clinical-trial definition, including phase 1, while the ACT rule has a defined scope and generally allows 21 days after first enrollment.
There is no difference.
Sections you finish are checked off in the contents.